Novartis’ Gilenya reduces brain shrinkage matters for people with MS
Patients who had the highest rates of brain shrinkage at two years had a higher risk of disability progression at four years
Author
Schizophrenia has group of eight genetically distinct disorders
Study could be a first step towards improved diagnosis and treatment for the debilitating psychiatric illness
Merck Serono to discontinue clinical development programme of tecemotide
The results of the recent trial in Japanese patients decreased the probability of current studies to reach their goals
Glenmark’s TRPA1 antagonist shows positive data
TRPA1 is an ion channel expressed on peripheral and spinal sensory neurons and it mediates pain signal transmission
Bone Therapeutics receives clearance
To investigate Allob’s potential to improve spinal fusion surgery outcomes
Spill resistant formulations: No crying over spilt syrups!
Adhithi Raghavan, Final Year B. Pharm. Student, Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, NMIMS…
Sanofi’s dengue vaccine candidate completes efficacy study
Second large-scale phase III study successfully meets primary endpoint with overall vaccine efficacy of 60.8 per cent and shows…
Novartis’ Ultibro Breezhaler reduces COPD flare ups
Once-daily Ultibro Breezhaler reduces exacerbations (flare ups) by 31 per cent compared to twice-daily Seretide Accuhaler in…
Novartis’ KAE609 shows promise as next generation treatment for malaria
KAE609 is the first antimalarial drug candidate with a novel mechanism of action to achieve positive clinical proof-of-concept in…
Merck Serono initiates phase II study of AntiPDL1 antibody in mMCC
mMCC is a rare and aggressive skin cancer lacking effective treatments